Sunshine Biopharma (SBFM)
NASDAQ:SBFM
Want to see SBFM full AI Analyst Report?
Top Page
Sunshine Biopharma
(NASDAQ:SBFM)
Select Model
Select Model
Rating:43Neutral
Price Target:
$2.50
▲(103.25% Upside)
Action:Reiterated
Date:06/03/26
The score is held down primarily by persistent operating losses and ongoing negative operating/free cash flow, alongside clear bearish technical trends (price far below key moving averages and negative MACD). Low balance-sheet leverage is a partial offset, but recent equity/warrant financing adds dilution risk and the negative P/E highlights that profitability remains unresolved.
Positive Factors
Regulatory approval — Rivaroxaban Canada
Regulatory approval for a widely used anticoagulant expands the company’s commercial portfolio into Canada, supporting recurring wholesale and pharmacy sales. This reduces product-launch risk, creates a durable revenue stream if launched effectively, and leverages existing distribution channels.
Negative Factors
Negative operating cash flow
Consistent negative OCF and FCF show operations do not self-fund growth or working capital needs, forcing dependence on external financing. Structural cash burn increases execution risk for product launches and prolongs reliance on capital markets, raising dilution and continuity concerns.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory approval — Rivaroxaban Canada
Regulatory approval for a widely used anticoagulant expands the company’s commercial portfolio into Canada, supporting recurring wholesale and pharmacy sales. This reduces product-launch risk, creates a durable revenue stream if launched effectively, and leverages existing distribution channels.
Read all positive factors
Sunshine Biopharma (SBFM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.46M
Dividend YieldN/A
Average Volume (3M)1.09M
Price to Earnings (P/E)―
Beta (1Y)1.50
Revenue Growth-2.05%
EPS Growth89.29%
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-87.00
Shares Outstanding2,123,635
10 Day Avg. Volume3,175,467
30 Day Avg. Volume1,091,586
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.14
P/FCF Ratio-0.93
Enterprise Value/Market Cap-0.90
Enterprise Value/Revenue-0.14
Enterprise Value/Gross Profit-0.42
Enterprise Value/Ebitda0.86
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4
Revenue Forecast (FY)$35.39M
Sunshine Biopharma Business Overview & Revenue Model
Company Description
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat ...
How the Company Makes Money
Sunshine Biopharma primarily makes money by commercializing pharmaceutical products, especially generic prescription drugs, and recognizing revenue from product sales into its distribution channels. Key revenue streams typically include: (1) sales...
Sunshine Biopharma Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.49M | 36.31M | 34.87M | 24.09M | 4.35M | 228.43K |
| Gross Profit | 11.53M | 11.92M | 10.67M | 8.34M | 1.70M | 110.60K |
| EBITDA | -5.71M | -4.15M | -5.14M | -3.82M | -26.45M | -12.09M |
| Net Income | -6.04M | -5.98M | -5.13M | -4.51M | -26.74M | -12.44M |
Balance Sheet | ||||||
| Total Assets | 27.93M | 30.08M | 30.56M | 27.35M | 29.55M | 2.20M |
| Cash, Cash Equivalents and Short-Term Investments | 6.91M | 9.12M | 9.69M | 16.29M | 21.83M | 2.05M |
| Total Debt | 744.84K | 812.42K | 952.48K | 657.71K | 765.26K | 1.90M |
| Total Liabilities | 6.41M | 7.04M | 7.06M | 6.14M | 7.92M | 1.99M |
| Stockholders Equity | 21.52M | 23.04M | 23.50M | 21.21M | 21.63M | 211.66K |
Cash Flow | ||||||
| Free Cash Flow | -5.51M | -5.51M | -14.85M | -9.56M | -5.55M | -1.83M |
| Operating Cash Flow | -5.69M | -5.33M | -12.53M | -8.78M | -5.25M | -1.83M |
| Investing Cash Flow | -764.80K | -836.31K | -2.32M | -656.15K | -14.62M | 0.00 |
| Financing Cash Flow | 4.41M | 4.75M | 9.29M | 3.43M | 39.47M | 2.90M |
Sunshine Biopharma Technical Analysis
Negative
1.23
Price Trends
8.06
Negative
9.88
Negative
12.58
Negative
Market Momentum
-1.79
Positive
29.94
Positive
15.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Negative. The current price of 1.23 is below the 20-day moving average (MA) of 4.77, below the 50-day MA of 8.06, and below the 200-day MA of 12.58, indicating a bearish trend. The MACD of -1.79 indicates Positive momentum. The RSI at 29.94 is Positive, neither overbought nor oversold. The STOCH value of 15.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SBFM.
Sunshine Biopharma Risk Analysis
Sunshine Biopharma disclosed 32 risk factors in its most recent earnings report. Sunshine Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
If we are unable to continue to meet the listing requirements of Nasdaq, our common stock will be delisted Q4, 2023
Sunshine Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $7.87M | -2.84 | -40.66% | ― | 2.00% | 94.31% | |
46 Neutral | $4.20M | -0.58 | -85.94% | ― | 26.83% | 48.18% | |
43 Neutral | $5.46M | -0.20 | -25.58% | ― | -2.05% | 89.29% | |
42 Neutral | $1.83M | -14.53 | -93.87% | ― | -6.14% | -24.22% | |
| ― | $2.88M | -0.21 | -9999.00% | ― | ― | 92.53% |
* Healthcare Sector Average
SBFM
Sunshine Biopharma
2.46
-12.64
-83.71%
SNOA
Sonoma Pharmaceuticals
1.14
-2.18
-65.66%
YCBD
cbdMD
0.72
-0.24
-24.69%
IMCC
IM Cannabis Corp
0.27
-2.49
-90.11%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
0.45
-4.13
-90.09%
Sunshine Biopharma Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Sunshine Biopharma Approves Dilutive Share and Warrant Actions
Negative
May 29, 2026
On May 28, 2026, Sunshine Biopharma reported that majority stockholder and CEO Dr. Steve N. Slilaty approved, by written consent, the issuance of more than 20% of the company’s outstanding common shares at a discount to Nasdaq’s minimu...
Business Operations and StrategyPrivate Placements and Financing
Sunshine Biopharma Completes $6 Million Unit Offering
Positive
May 19, 2026
On May 18, 2026, Sunshine Biopharma Inc. entered into a placement agent agreement with Aegis Capital Corp. for a reasonable best‑efforts public offering of 12 million common or pre‑funded units, each including one share or pre‑fu...
Business Operations and StrategyPrivate Placements and Financing
Sunshine Biopharma Engages Aegis for Warrant Solicitation
Neutral
Mar 9, 2026
On March 6, 2026, Sunshine Biopharma Inc. signed a three‑month engagement agreement with Aegis Capital Corp. for Aegis to act as warrant solicitation agent on a best‑efforts basis to induce the exercise of the company’s outstandi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.